Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey

References

• WHO. Meeting of the strategic advisory group of experts on immunization, November 2013—conclusions and recommendations. Wkly Epidemiol Rec. 2014;89:1–20.
   PubMedGoogle Scholar
• Global Polio Eradication Initiative. The polio endgame strategy 2019–2023. [accessed 2019 Aug 28]. http://polioeradication.org/wp-content/uploads/2019/06/English-polio-endgame-strategy.pdf.
   Google Scholar
• Van den Ent M, Swift RD, Anaokar S, Hegg LA, Eggers R, Cochi SL. Contribution of global polio eradication initiative funded personnel to the strengthening of routine immunization programs in the 10 focus countries of the Polio Eradication and Endgame Strategic Plan. J Infect Dis. 2017;216(suppl 1):S244–49. doi:10.1093/infdis/jiw567.
   PubMedGoogle Scholar
• O’Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–82. doi:10.1016/S1473-3099(15)00219-4.
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–69. doi:10.1016/S0140-6736(16)00703-0.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SAC, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16:321–30. doi:10.1016/S1473-3099(15)00488-0.
   PubMed Web of Science ®Google Scholar
• Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, Wang W, Wang H, Guo S, Li C, et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial. Hum Vaccin Immunother. 2017;13:1–10. doi:10.1080/21645515.2017.1288769.
   PubMed Web of Science ®Google Scholar
• Li RC, Li CG, Wang HB, Luo H-M, Li Y-P, Wang J-F, Ying Z-F, Yu W-Z, Shu JD, Wen N, et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China. J Pediatric Infect Dis Soc. 2016;5:287–96. doi:10.1093/jpids/piv017.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015;386:2413–21. doi:10.1016/S0140-6736(15)00237-8.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain-based inactivated poliovirus vaccine. J Infect Dis. 2016;214:1728–34. doi:10.1093/infdis/jiw433.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016;44:581–87. doi:10.1016/j.biologicals.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Lu L, Li X, Zhang H, Liu D, Zhang Z, Wang H, Liu F, Ning Z, Li J, Pang X, et al. Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants. Vaccine. 2015;33:4653–58. doi:10.1016/j.vaccine.2014.08.091.
   PubMed Web of Science ®Google Scholar
• Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–76.
   PubMedGoogle Scholar
• Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Steven Oberste M, Zaidi SS, Alam MM, Quadri F, Sutter RW, et al. Immunogenicity of different routine poliovirus vaccination schedules: a randomized,controlled trial in Karachi, Pakistan. J Infect Dis. 2018;217:443–50. doi:10.1093/infdis/jix577.
   PubMed Web of Science ®Google Scholar
• Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16:1377–84. doi:10.1016/S1473-3099(16)30169-4.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Enterline JC, Boone EJ, Klutch MJ. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures[J]. J Biol Stand. 1983;11(2):91–97. doi:10.1016/S0092-1157(83)80031-6.
   PubMedGoogle Scholar
• Li XM, Zhang ZJ, Wang HH, Liu F, Zhang L-W, Chu P, Xu Y, Zhang H-R, Li J, Liu D-L, et al. Immunogenicity and safety of a booster dose of inactivated polio vaccine[J]. Zhonghua Yu Fang Yi Xue Za Zhi. 2013;47(10):905–09.
   PubMedGoogle Scholar
• Faden H, Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines[J]. Am J Dis Child. 1992;146(11):1320–23. doi:10.1001/archpedi.1992.02160230078023.
   PubMedGoogle Scholar
• Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses[J]. J Infect Dis. 1990;162(6):1291–97. doi:10.1093/infdis/162.6.1291.
   PubMed Web of Science ®Google Scholar
• Halsey NA, Blatter M, Bader G, Thoms ML, Willingham FF, O’Donovan JC, Pakula L, Berut F, Reisinger KS, Meschievitz C, et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine[J]. Pediatr Infect Dis J. 1997;16(7):675–79. doi:10.1097/00006454-199707000-00010.
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Dueger EL, Omer SB, Melville A, Nates S, Laassri M, Chumakov K, Halsey N. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants[J]. J Infect Dis. 2007;196(5):692–98. doi:10.1086/520546.
   PubMed Web of Science ®Google Scholar
• Gaensbauer JT, Gast C, Bandyopadhyay AS, O’Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, et al. Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame[J]. Clin Infect Dis. 2018;67(S1):S57–65. doi:10.1093/cid/ciy649.
   PubMedGoogle Scholar
• Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines[J]. J Infect Dis. 1993;168(2):452–54. doi:10.1093/infdis/168.2.452.
   PubMed Web of Science ®Google Scholar
• Guérin N, Bregère P, Caudrelier P, Raynaud O. Neutralizing antibody response to oral poliovirus vaccine after primary immunization with inactivated poliovirus vaccine[J]. Eur J Clin Microbiol Infect Dis. 1998;17(11):815–16. doi:10.1007/s100960050198.
   PubMed Web of Science ®Google Scholar
• Laassri M, Lottenbach K, Belshe R, Wolff M, Rennels M, Plotkin S, Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains[J]. J Infect Dis. 2005;192(12):2092–98. doi:10.1086/498172.
   PubMed Web of Science ®Google Scholar
• Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine [J]. J Infect Dis. 1993;168(5):1105–09. doi:10.1093/infdis/168.5.1105.
   PubMed Web of Science ®Google Scholar
• Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines[J]. J Infect Dis. 1991;164(1):191–94. doi:10.1093/infdis/164.1.191.
   PubMed Web of Science ®Google Scholar
• Minor PD, Dunn G, Ramsay ME, Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains[J]. J Med Virol. 2005;75(1):153–60. doi:10.1002/jmv.20250.
   PubMed Web of Science ®Google Scholar
• Parent Du Chatelet I, Merchant AT, Fisher-Hoch S, Luby SP, Plotkin SA, Moatter T, Agboatwalla M, Mc Cormick JB. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules[J]. Vaccine. 2003;21:1710–18. doi:10.1016/S0264-410X(02)00523-6.
   PubMed Web of Science ®Google Scholar
• Wicker S, Rabenau H, Gottschalk R, Doerr HW, Allwinn R. seroprotection rates of vaccine-preventable and blood-transmissible viral infections (measles,mumps, rubella, VZV, polio, HBV, HCV, HIV) in medical students[J]. Med Microbiol Immunol. 2007;196:145–50. doi:10.1007/s00430-007-0036-3.
   PubMed Web of Science ®Google Scholar
• Diedrich S, Schreier E. The German Health Interview and examination survey for children and adolescents: state of immunity against poliomyelitis in German children[J]. Bundesgesundheitsblatt. 2007;50(5–6):771–74. doi:10.1007/s00103-007-0239-1.
   Google Scholar
• Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. seroprotection rates of antibodies to poliovirus in individuals living in Portugal, 2002[J]. Euro Surveill. 2007;12(6):E7–E8. doi:10.2807/esm.12.06.00717-en.
   PubMedGoogle Scholar
• Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: alurking danger? [J]. BMC Infect Dis. 2012;12:24. doi:10.1186/1471-2334-12-24.
   PubMed Web of Science ®Google Scholar
• James TG, Chris G, Ananda SB, Miguel O’, Xavier Saez-Llorens, Luis R, Eduardo Lopez-Medina, Mario M, William CW, Steven OM, et al. Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame. Clinc Infectious Diseases 2018;67 (Suppl 1):S57–65.
   PubMed Web of Science ®Google Scholar
• Ning W, Zhijie A, Hong Y, et al. Considerations and suggestions for polio vaccination strategies in China [J]. Chin J Vaccines Immun. 2018;24:349–53.
   Google Scholar